AEZS Aeterna Zentaris Inc

USD 6.89 -0.41 -5.616438
Icon

Aeterna Zentaris Inc (AEZS) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 6.89

-0.41 (-5.62)%

USD 0.02B

3.99K

N/A

N/A

Icon

AEZS

Aeterna Zentaris Inc (USD)
COMMON STOCK | NSD
USD 6.89
0.00 0
Take a Tour
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Slightly Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 0.02B

N/A

USD 6.89

Aeterna Zentaris Inc (AEZS) Stock Forecast

N/A

Based on the Aeterna Zentaris Inc stock forecast from 0 analysts, the average analyst target price for Aeterna Zentaris Inc is not available over the next 12 months. Aeterna Zentaris Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Aeterna Zentaris Inc is Slightly Bearish, which is based on 3 positive signals and 7 negative signals. At the last closing, Aeterna Zentaris Inc’s stock price was USD 6.89. Aeterna Zentaris Inc’s stock price has changed by -15.56% over the past week, -16.28% over the past month and -39.35% over the last year.

No recent analyst target price found for Aeterna Zentaris Inc
No recent average analyst rating found for Aeterna Zentaris Inc

Company Overview Aeterna Zentaris Inc

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an oral...Read More

https://www.zentaris.com

315 Sigma Drive, Summerville, SC, United States, 29486

0

December

USD

USA

Adjusted Closing Price for Aeterna Zentaris Inc (AEZS)

Loading...

Unadjusted Closing Price for Aeterna Zentaris Inc (AEZS)

Loading...

Share Trading Volume for Aeterna Zentaris Inc Shares

Loading...

Compare Performance of Aeterna Zentaris Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for AEZS

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Aeterna Zentaris Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc -1.75 (-0.36%) USD124.65B 31.35 20.00

ETFs Containing AEZS

Symbol Name AEZS's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Aeterna Zentaris Inc (AEZS) Stock

Stock Target Advisor's fundamental analysis for Aeterna Zentaris Inc's stock is Slightly Bearish.

Unfortunately we do not have enough data on AEZS's stock to indicate if its a good dividend stock.

Unfortunately we do not have enough data on AEZS's stock to indicate what its average analyst target is.

AEZS stock's Price/Earning ratio is 14.80. Our analysis grades AEZS stock's Price / Earning ratio at F. This means that AEZS stock's Price/Earning ratio is above 65.99999999999999% of the stocks in the Biotechnology sector in the NSD exchange. Based on this AEZS may be a overvalued for its sector.

The last closing price of AEZS's stock was USD 6.89.

The most recent market capitalization for AEZS is USD 0.02B.

Unfortunately we do not have enough analyst data on AEZS's stock to indicate whether its price will go up or not.

We can't find any ETFs which contains Aeterna Zentaris Inc's stock.

As per our most recent records Aeterna Zentaris Inc has 0 Employees.

Aeterna Zentaris Inc's registered address is 315 Sigma Drive, Summerville, SC, United States, 29486. You can get more information about it from Aeterna Zentaris Inc's website at https://www.zentaris.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...